Registry for MAASTRO rectal applicator treatment
Part of Cancer, Digestive system clinical trials.
This study collects data from people treated with a special rectal applicator for rectal cancer. The goal is to observe long-term outcomes and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with rectal cancer (or very strong suspicion based on imaging).
- Your treatment involves the MAASTRO HDR rectal applicator.
- You agree to have your medical data collected for research over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of internal radiation therapy, called brachytherapy, delivered through a special applicator placed inside the rectum. It aims to treat rectal cancer while possibly reducing side effects compared to external radiation.
This study is a registry that collects information about people with rectal cancer to help doctors learn more about the disease and its treatment. It focuses on patients receiving a certain treatment plan (TNT) or with a specific genetic marker (dMMR/MSI-H), and aims to improve future care.
This study looks at patterns in the gut microbiome (gut bacteria) and gut chemicals (metabolites) to predict how rectal cancer may do after planned surgery. By understanding these markers, researchers hope to better forecast prognosis and tailor follow-up.
This trial tests a new type of radiation therapy that uses real-time MRI imaging to adjust the radiation precisely to your tumor. It is designed to improve the accuracy of treatment for locally advanced rectal cancer, potentially reducing damage to nearby healthy tissue.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.